Abraxane has been rejected by NICE for use in ... The list price of nab-paclitaxel is £246 per 100 mg vial (excluding VAT). The company's submission also states that a 250 mg vial will be ...

Drug major Cipla on Friday said it has received approval from the US health regulator to market a generic cancer treatment drug.

Abraxane plus gemcitabine demonstrated a statistically significant improvement in median overall survival compared to gemcitabine alone (8.5 vs. 6.7 months); a 28% overall reduction in risk of death.

Cipla's Protein-bound Paclitaxel is an AB-rated generic therapeutic equivalent version of Bristol Myers Squibb's Abraxane for Injectable Suspension 100 mg/vial. Protein-bound Paclitaxel is indicated ...

It is an AB-rated generic therapeutic equivalent version of Bristol Myers Squibb’s Abraxane for Injectable Suspension 100 mg/vial. Cipla expects to launched the product in the U.S. by September.